About us
Company profile
Dedicate to be the top provider of precision medicine treatment
Suzhou Four Health Pharmaceuticals Co.,Ltd. (4Health) is a clinical stage integrated innovative precision optical & radiopharmaceutical theranostic drug development enterprise based on China and facing the world.
R&D pipeline
Expert Staff
History
We are determined to become a leader in the field of precision medicine and set an industry benchmark in transformation, research & development, quality standards and production technology. With this as our goal, we give full play to our creativity, take the initiative and innovate in our work.
Founded in August 2021
Obtained over 15 millions USD Venture Capital Investment
Our Management Team
Dr. Guanli WANG
Founder & CEO
China Earliest Precision Targeted Radiopharmaceutical R&D Business Operator. In 2013，he has hosted China investment into German OctreoPharm Sciences GmbH (OPS). In 2015, OPS has successfully 100% sold for French Ipsen S.A.. In 2016 &2017, Dr. WANG has Seed & Pre-IPO invested Australian Telix Pharmaceuticals Limited (Until 2023, Telix is Australian one of best biopharma). In 2018, Dr. WANG has invested Hong Kong NanoMab Biotech Company which focused on anti-cancer VHH nano anti-body imaging and radiopharmaceutical therapies. In 2021, NanoMab has successfully sold to another Australian List Company – Radiopharm Theranostics Ltd. (RAD). Right now Dr. WANG as young Chinese radiopharmaceutical business Entrepreneur, has founded Shanghai TheragNova Med-Tech & Suzhou Four Health Pharmaceuticals Companies to continue the Targeted Precision Theranostic Innovational Platform development. The team members he has led comprise experts from China, Europe, and the United States, with global work capabilities.
Prof. Weibo CAI (PhD, FAIMBE, FSNMMI, FRSC)
CSO, North American Company
Dr. Weibo CAI is a Distinguished Professor at the University of Wisconsin-Madison, renowned for his outstanding achievements in radiology, medical physics, materials science and engineering, and pharmaceutical sciences. He has published over 390 peer-reviewed articles, edited 3 books, and given over 330 lectures. Dr. CAI has received numerous honors and awards, including Fellow of the American Institute for Medical and Biological Engineering (AIMBE), Fellow of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), Fellow of the Royal Society of Chemistry (RSC), and is currently serving as Editor-in-Chief of the Journal of Nanobiotechnology and The American Journal of Nuclear Medicine and Molecular Imaging. His research at UW-Madison focuses on molecular imaging and nanobiotechnology.
Prof. Wenhua HUANG
Co-Founder & Vice President, CMC Director, MBA
The China first person obtained the PD-1/PD-L1 VHH camel single domain nano antibody radionuclide diagnostic drugs phase II clinical certificate in UK. Dr. HUANG was China General Manager of Shanghai NanoMab Biotech Limited Company. He was director of Transformation Department of 1st People’s Hospital of Shanghai Jiao Tong University, and Senior VP & CMC Director of Cell Signaling (Maryland) Corporation, and Patent Director of British GeneMedix (Shanghai) Company, which listed in London Stock Exchange in 2002.
Prof. Hao HONG (PhD)
Co-Founder & CTO
Professor Hong received his PhD in Biochemistry from Nanjing University. His main research interests are in cutting-edge fields including molecular imaging and functional nanomaterials, focusing on integrated diagnostics and therapeutics of diseases. Professor Hong has published over 110 high-impact research papers. He has authored multiple book chapters and co-authored several patents. He has successfully obtained funding from national science foundations in China and foundations in the US, and won many awards at international conferences (e.g. 2012 and 2016 Berson-Yalow Award from SNMMI), fully demonstrating his outstanding academic achievement.
Dr. Jiao KUANG
Clinical Head
Seasoned industry leader with over 20 years of experience in global clinical development across multiple therapeutic areas. Successful track record of IND and NDA submissions and approvals from both China NMPA and US FDA. Expertise spans a breadth of innovative drugs including antibody drugs, ADCs, small molecule inhibitors, cell therapies and radioactive medical devices. Held senior executive roles in various biotech companies, heading up global clinical research programs. Led collaborative GCP teams with a culture of operational excellence and continuous improvement.
Dr. Fangjie SHU
Co-Founder & Board Secretary
Recommender of Precision Oncology Project of Chinese Government Science & Technology Bureau. Dr. SHU was Business Operation & Finance Director of AccuGen (Suzhou) Group, and she is responsible for the global biomedical enterprise liaison of China Nanjing University Biomedical Association. Currently She coordinates internal management of the company and integrate external resources; assists in the financing sector of the company. She is good at public relationship and crisis management. Dr. SHU was successively served as reporter, host and editor in Suzhou radio & TV station. Her Master degree graduated in China Nanjing University.
Board of Directors
Dr. Guanli WANG
Chairman of the Board
CEO of Suzhou Four Health Pharmaceuticals Co.,Ltd
Prof. Hao HONG
CTO of Suzhou Four Health Pharmaceuticals Co.,Ltd
Dr. Jolee LI
Senior Partner, Shanghai Langsheng Investment
Precision Oncology Venture Capital